RET fusion may be responsible for the pathogenesis in patients with lung cancer without mutations in EGFR, ALK, or ROS1, which may be related to the RET-induced promotion of apoptosis resistance (Drilon et al., 2020). The gene discussed is ALK; the disease is lung cancer.